KEY TAKEAWAYS
- The phase III OlympiAD trial studied the efficacy of olaparib vs. capecitabine in gBRCAm HER2-negative mBC.
- The study’s primary endpoint was PFS, confirming that olaparib showed longer PFS vs TPC or capecitabine. It had an acceptable safety profile in gBRCAm HER2-negative mBC.
The phase III OlympiAD trial divided patients (pts) into two groups: one receiving olaparib 300 mg twice daily (205 participants) and the other TPC (97 participants, with 43 of them getting capecitabine 2500 mg/m2 for 14 out of 21 days). The analysis considered all pts and those with triple-negative BC (TNBC).
Post-hoc analyses compared olaparib with capecitabine in pts who were eligible for capecitabine (essentially, those who would have been given capecitabine if they had been in the TPC group). The main endpoint was PFS, evaluated by an independent central review.
Olaparib consistently showed a better median PFS than TPC or capecitabine across all analyzed groups. The safety of the drug matched previously published findings.
Olaparib exhibited a longer PFS when compared to TPC or capecitabine, maintaining an acceptable safety profile for gBRCAm HER2-negative mBC pts. These results can guide the choice of optimal treatment for pts with gBRCAm BC. However, it’s important to note the limitations of this analysis, mainly its exploratory approach and the limited sample size.
Clinical Trial: https://classic.clinicaltrials.gov/ct2/show/NCT02000622
Robson, M., Delaloge, S., Domchek, S.M., Conte, P.F., Im, S., Xu, B., Armstrong, A., Masuda, N., Hettle, R., Fielding, A., Tung, N.M., Senkus-Konefka, E. OLYMPIAD: EXPLORATORY ANALYSIS OF OLAPARIB VS CAPECITABINE IN PATIENTS WITH GERMLINE BRCA-MUTATED (GBRCAM) METASTATIC BREAST CANCER (MBC). Annals of Oncology (2023) 8 (1suppl_4): 101223-101223. 10.1016/esmoop/esmoop101223.
